EcoDrugPlus

Nociceptin Receptor-Like

Ensembl ID : ENSSTUG00000010880
Gene Symbol: LOC115165292
3 Cross references
184 Possible Orthologues:

Nociceptin Receptor-Like

Ensembl ID : ENSSTUG00000006730
Gene Symbol: LOC115168727
3 Cross references
185 Possible Orthologues:

Nuclear Factor Nf-Kappa-B P105 Subunit-Like

Ensembl ID : ENSSTUG00000031620
Gene Symbol: LOC115173310
2 Cross references
194 Possible Orthologues:

Nuclear Factor Erythroid 2-Related Factor 2-Like

Ensembl ID : ENSSTUG00000042007
Gene Symbol: LOC115179289
3 Cross references
203 Possible Orthologues:

Nuclear Factor Erythroid 2-Related Factor 2-Like

Ensembl ID : ENSSTUG00000043132
Gene Symbol: LOC115160786
3 Cross references
199 Possible Orthologues:

Nuclear Factor Erythroid 2-Related Factor 2-Like

Ensembl ID : ENSSTUG00000033577
Gene Symbol: LOC115155481
3 Cross references
199 Possible Orthologues:

Nuclear Factor Kappa B Subunit 1

Ensembl ID : ENSSTUG00000039971
Gene Symbol: NFKB1
3 Cross references
194 Possible Orthologues:

Nuclear Receptor Subfamily 3 Group C Member 1

Ensembl ID : ENSSTUG00000016475
Gene Symbol: NR3C1
3 Cross references
199 Possible Orthologues:

Nuclear Receptor Subfamily 3 Group C Member 1

Ensembl ID : ENSSTUG00000005575
Gene Symbol: NR3C1
3 Cross references
198 Possible Orthologues:

Nucleotide-Binding Oligomerization Domain-Containing Protein 2-Like

Ensembl ID : ENSSTUG00000011203
Gene Symbol: LOC115167029
3 Cross references
165 Possible Orthologues:

Opioid Receptor Delta 1

Ensembl ID : ENSSTUG00000020255
Gene Symbol: OPRD1
3 Cross references
186 Possible Orthologues:

Opioid Receptor Kappa 1

Ensembl ID : ENSSTUG00000020145
Gene Symbol: OPRK1
3 Cross references
192 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).